Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sandoz Group Ltd ( (CH:SDZ) ) has shared an update.
Sandoz has announced a strategic agreement to acquire Just-Evotec Biologics EU SAS, enhancing its in-house biosimilar development and manufacturing capabilities. This acquisition aligns with Sandoz’s strategy to capitalize on the projected USD 300 billion biosimilar market over the next decade, providing the company with continuous manufacturing technology and securing control over its pipeline. The transaction, valued at approximately USD 350 million, includes an indefinite technology license and reconfigures the existing partnership model to align incentives through license fees and development-related expenses.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF55.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz is a global leader in affordable medicines, headquartered in Basel, Switzerland. It has a diverse portfolio of approximately 1,300 products addressing various diseases, from the common cold to cancer. The company is known for its pioneering efforts in the pharmaceutical industry, including the development of the world’s first biosimilar in 2006.
Average Trading Volume: 762,058
Technical Sentiment Signal: Buy
Current Market Cap: CHF24.36B
For detailed information about SDZ stock, go to TipRanks’ Stock Analysis page.